Governance

Jérôme Bédier is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career. With 25 years' experience, notably with the Novasep group, Jérôme Bédier held positions in business development and operations management before taking over strategic management of Novasep's biopharmaceutical business and its three European sites. He then rolled out this investment program as President Biopharma. In 2021, Jérôme joined Cell-Easy as Chief Operating Officer, where he oversaw the structuring and launch of CDMO activities in cell therapy.
His ambition for Flash Therapeutics is to strengthen its position as a global CDMO expert thanks to its expertise and its two DNA and RNA lentiviral technologies.

Valentin graduated from Toulouse Business School with a DCG in 2017, then from Toulouse School of Management with a Master 2 in Audit and Organization Management in 2019. Since May 2020, he has been in charge of finance, accounting and management control for Flash Therapeutics. He previously spent 3 years as a portfolio manager with an accounting firm (2014 to 2017) and 2 years as a Management Controller with the GRDF group (where he was in charge of OPEX budget management, real estate owned by the regional entity) (2018 - 2020).

With a Master's degree in Human Resources Management, Aurélie began her career with Randstad in 2018 and joined Flash Therapeutics in 2020 as HR Assistant. In particular, Aurélie is in charge of steering the skills development plan, recruiting new profiles and engaging employees, as well as leading internal communication with employees whether individual or collective. Her mission is to foster an inclusive, respectful and stimulating working environment, where everyone can flourish and contribute to the company's success.

Virginie has spent over 20 years in the field of drug products manufacturing, holding various positions in Regulatory Affairs, Quality Control and Quality Assurance. She graduated from the Faculty of Pharmaceutical Sciences in Toulouse in 2001 and from the Paris V Faculty of Pharmaceutical Sciences in 2012, as a certified auditor for pharmaceutical industry. Virginie subsequently acquired in-depth knowledge of Good Manufacturing Practices while working at SANOFI and then at CDMO UNITHER. She joined Flash Therapeutics in 2023 as Quality Director, to support and prepare the company for tomorrow's developments and challenges.

Christine obtained her PhD in immunology in 2000 and then worked for eight years in the United States and France, where she successfully led various projects examining immune responses in different pre-clinical models for autoimmune diseases. She gained experience in in vivo eengineering, biochemistry and cell biology during these several years of academic research before becoming the head of the Animal Models department at Vectalys in 2008. Christine then participated in the development and scientific outreach of the LentiFlash technology and immunotherapy-related projects for Flash Therapeutics (formerly Vectalys). Today, her knowledge is a key element in the development of the company's innovation projects and strategies.

After obtaining his engineering degree in mechanical engineering (specialization in biomechanics/biomaterials) at the University of Technology of Compiègne (UTC), Clément joined the pharmaceutical industry at SANOFI in the industrial department where he piloted the installation of syringe filling lines in sterile environments. After this experience, he joined the company CARMAT which designs and develops a human artificial heart where he stayed for 13 years. First as a process development manager, he worked mainly on all aspects related to clean room manufacturing, contamination control and sterilization processes. Then, he became production manager before taking over the project management for the design and deployment of the new prosthesis manufacturing site. Finally, during his last 3 years, as Industrial Development Manager, he worked on the optimization of the manufacturing processes in order to increase the production rate.
Clément joined Flash Therapeutics in 2021 as Industrial Development and Production Manager in order to support the company in its industrial ramp-up to meet the growing demands of our customers. 

Michel Baijot, Ph.D., has served as board director since 2022. Dr Michel Baijot is board director of Sinovac. Chairman of the White Fund and OncoRadiomics.
He has spent more than 25 years in various executive positions with bioMerieux as Corporate Director Molecular Diagnostics, with Innogenetics as VP of Business Development, with GSK Vaccines as VP of strategy, licensing and M&A, with Janssen Crucell Vaccines as Chief Business Officer, with Serum Institute of India as Executive Director Europe.
He has been Chairman of the Belgian Biotech Association for 5 years.
Dr Michel Baijot is a chemical engineer and holds a Ph.D. in molecular biology from University of Louvain (Belgium).
 

Jacques Rossignol is a Managing Partner and Co-Founder of TechLife Capital. He has been a private equity growth investor for more than 20 years, has covered the healthcare industry since 2004 and the technology industry since 1998. Aside from Flash Therapeutics, he is currently the President of the Supervisory Board of XPath Groupe (cancer diagnosis services), of Mitem Pharma (pharmaceutical laboratory for drugs of major therapeutic interest), and of Evolutis (orthopedic implants), a member of the Supervisory Board of Quinten (data science expert of AI-based solutions for pharma and healthcare services) and used to be a Member of the Supervisory Board of Synerlab (a pharmaceutical CDMO). Before TechLife Capital, he was head of France at Alpha Private Equity, Managing Partner at 21 Invest and Director at Ekkio. He started his career in Investment Banking at BNP Paribas and Goldman Sachs (Paris, London). He is a graduate from Ecole Polytechnique and holds an MBA degree from the Harvard Business School.

Grégoire Cayatte is a Managing Partner and Co-Founder of TechLife Capital. He has 18 years of operational and technological experience with Devoteam, a tech services listed company where he was CFO and a member of the Executive Committee. He led more than 50 acquisitions in 20 countries and actively contributed to the creation of 7 platforms, notably in the cybersecurity, migration to the cloud, and digital transformation. Aside from Flash Therapeutics, he is currently a Supervisory Board member of XPath Groupe (cancer diagnosis services), MyData-Trust (GDPR services for clinical trials), Quinten (data science expert of AI-based solutions for pharma and healthcare services), Maxxing (loyalty management Saas) and CNSI (e-commerce solutions). Grégoire started his career in Investment Banking at Lazard and BNP Paribas. He is a graduate from Ecole Polytechnique, Ecole des Ponts ParisTech and from Institut d’Etudes Politiques.

Franck Lescure is in charge of Life Sciences investments at AURIGA Partners. He manages the Fund AURIGA IV Bioseeds specialized in Infectiology and Microbiology and is directly involved in commitments of AURIGA Partners Funds in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab’entech, Flashcell, Pherecydes, Median Technologies (Alternext: ALMDT), Nosopharm and Pylote. Before Auriga Partners, Franck has been part as a scientist of the five initial years of Genset, one of the first French biotech startups, he has spent several years in the Air Liquide group and has been in charge of several investments as member of the Venture Capital team of Crédit Lyonnais Private Equity which became Omnes Capital. Franck is an alumnus of the EcoleNormaleSupérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs

Graduate of ESC Reims (RMS) and holder of DESCF, Claudia DAUGAN began her career in 1997 at KPMG Audit in Paris where she carries out statutory auditing and consulting assignments for a banking clientele. In 2000, she joined Calyon's Equity Capital Market team, which is responsible for structuring and executing the issuance of securities of major groups (listed equities and convertible bonds). From 2004 to 2009, after joining the Bordeaux region, she continued her career at Crédit Lyonnais as Deputy of Corporate Finance. She accompanies SME managers and buyers of companies in their "equity financing". Since 2009, Claudia DAUGAN has strengthened the team of investors of GALIA Gestion as Senior Business Manager and then Director of Investments. She currently follows a portfolio of a dozen companies in diversified business sectors (ICT, Services, Medical).

Alain Baudant is a shareholder and founder of FADièse 2 and FADièse 3. He is also Director and Chairman of Fondation Saint-Pierre from 2019 to 2023 (children's hospital and integration of young people in difficulty in Montpellier) and Associate Judge at the Cour nationale du droit d'asile from 2018 to 2022. An alumnus of the Ecole Normale Supérieure, Doctor of Letters and IMD graduate, he held several positions from 1995 to 2018: Chairman of Papeteries de Condat, Chairman of Leefung-Asco (Hong Kong, China), Managing Director of the Paper Division and finally Vice-President Planning and Strategic Development of the SmurfitKappa Group.

Luc AGUILAR gathers 20 years of experience in the biotech, pharmaceutical and the cosmetic Industry. He joined L’Oreal seven years ago to build the biotechnology Department in Advance Research. He is now leading Advanced Research activities from Scientific Knowledge to Clinical Performance for skin and hair categories. From 2005 to 2011, he was at Pierre Fabre’s Group, a mid-size pharmaceutical company, as Vice-President Scientific Affairs. During this period, he set up and led an innovation structure dedicated to clinical proof of concept studies. Prior to that, he managed operations in Biotech and start-up companies in genomics for corporate clients from 1995 to 2001. He earned a MS in Biotechnology from I.N.S.A.Toulouse, France and a PhD experience at Pierre et Marie Curie University.